Introduction

Osteoarthritis (OA) is one of the most common causes of knee pain and stiffness, often disrupting everyday life. For many, knee surgery such as a meniscectomy—where damaged meniscal cartilage is removed—offers relief initially. However, some patients continue to struggle with persistent aches, reduced shock absorption, and limited knee function even after surgery. These lingering symptoms can make walking, standing, and other daily activities difficult. While conventional treatments provide some help, new options like Arthrosamid—a specialised injectable hydrogel—are gaining interest. This article reviews the challenges faced by those with ongoing post-meniscectomy OA symptoms and looks at how Arthrosamid might offer improved joint comfort and mobility.

Understanding Post-Meniscectomy Knee Symptoms within Osteoarthritis

A meniscectomy is often performed to remove torn or damaged meniscus tissue, giving short-term pain relief and improving knee movement. Yet the meniscus is essential as a shock absorber and stabiliser within the knee joint. When part or all of this tissue is removed, osteoarthritis can develop or progress more quickly because the cartilage and bone experience greater stress and wear.

Magnetic resonance imaging (MRI) studies provide important insights into the risk of ongoing joint degeneration. Research has shown that “presence of bone marrow oedema on MRI for acute knee injury is strongly predictive for new onset or progression of degenerative change of the femorotibial joint on follow-up MRI one year after trauma” (Ericsson, Ringsberg & Dahlberg, 2009). In simpler terms, swelling inside the bone following injury often signals worsening joint damage later on. This deterioration is linked to symptoms like aching pain, swelling, and stiffness, which can severely restrict activities such as walking and stair climbing. The same study also found “a significant association between new or progressive degenerative change and clinical outcome (non-recovery),” highlighting why many patients don’t fully recover after meniscus surgery. These findings emphasise the need for treatments that specifically target the challenges of post-meniscectomy osteoarthritis.

Arthrosamid: A Novel Solution for Persistent Knee Discomfort

Arthrosamid is an innovative injectable treatment designed to support joints affected by OA. Unlike traditional painkillers or physical therapy, Arthrosamid is gently placed inside the knee joint, where it acts as a soft cushioning gel to help absorb shocks and ease stress on the worn cartilage and bone surfaces.

This technology offers a new avenue for those who continue to feel persistent aches and reduced knee function after meniscectomy. Recent studies have found that “polyacrylamide hydrogel (PAAG) provided improvement in knee OA symptoms over 24 months, in older, non-diabetic patients with lower KL grades,” referring to milder stages of OA (Gao et al., 2025). While early results are promising, researchers also advise caution as “the absence of a control group and limited outcome measures should be considered.” In other words, Arthrosamid works best as part of a broader care plan tailored to each patient, rather than as a miracle cure.

The Professional Care Environment: Excellence in Patient Support

Treating post-meniscectomy osteoarthritis effectively requires more than innovative products; it demands expert care within a supportive environment. MSK Doctors demonstrate this holistic approach, combining advanced treatments like Arthrosamid with thorough clinical assessments and personalised rehabilitation programmes.

Professor Paul Lee is a highly respected orthopaedic specialist who leads clinical efforts in this area. His extensive experience and ambassadorial roles in professional societies highlight his dedication to advancing musculoskeletal health with a patient-centred focus. At MSK Doctors, patients benefit from careful evaluation and ongoing monitoring to ensure treatment fits their individual needs.

Experts also stress that while bone cement remains essential for serious trauma cases, patients with post-meniscectomy OA often respond better to less invasive options like Arthrosamid injections. This approach aligns with guidance from British surgical societies that advocate tailored strategies aiming to preserve natural joint function and improve quality of life.

Patient Perspectives and Moving Forward

For patients, Arthrosamid offers renewed hope in managing stubborn knee symptoms after meniscectomy. A recent study reported that “314 knees (269 patients) with OA were treated with PAAG and followed up over 2 years,” noting significant improvements in certain patient groups (Gao et al., 2025). It also highlighted that “patients with higher-grade knee OA were more likely to have total knee replacement surgery,” underscoring the importance of timely and appropriate treatment choices. Although some complications occurred, users generally experienced better comfort and mobility, reinforcing the need for close follow-up and personalised care.

Looking ahead, the future of post-meniscectomy OA treatment will likely involve combining innovations like Arthrosamid with physiotherapy, lifestyle changes, and selective surgery when necessary. Ongoing research will help fine-tune patient selection and maximise treatment benefits.

Thanks to dedicated specialists such as Professor Paul Lee and centres like MSK Doctors, patients with complex osteoarthritis symptoms can expect continued improvements in care quality. Their expert collaboration promises to improve day-to-day life for those living with persistent knee challenges after meniscectomy.

This article has provided an accessible yet detailed overview of how Arthrosamid can support patients struggling with post-meniscectomy osteoarthritis, offering insight into evolving treatments, expert care, and patient outcomes.

References

• Ericsson, Y., Ringsberg, K., & Dahlberg, L. (2009). Self-efficacy, physical activity and health-related quality of life in middle-aged post meniscectomy patients: A comparison to an age-matched control-group. Osteoarthritis and Cartilage, 17, S290. https://doi.org/10.1016/S1063-4584(09)60312-5
• Gao, H. C. K., Akhtar, M., Creedon, C., Nar, Ö. O., & Lee, P. Y. (2025). The impact of patient factors on the minimal clinically important difference of Arthrosamid polyacrylamide hydrogel injection for knee osteoarthritis: A cohort study. Osteoarthritis and Cartilage. https://doi.org/10.1016/j.joca.2025.02.648
• Gao, H. C. K., Akhtar, M., Creedon, C., Nar, Ö. O., Verma, T., & Lee, P. Y. F. (2025). Polyacrylamide hydrogel injections in knee osteoarthritis: A PROMs-based 24 month cohort study. Journal of Clinical Orthopaedics and Trauma. https://doi.org/10.1016/j.jcot.2025.103136